Astrel Genome Profile
Key Indicators
- Authorised Capital ₹ 10.00 Cr
as on 04-07-2024
- Paid Up Capital ₹ 3.00 Cr
as on 04-07-2024
- Company Age 19 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 35.72%
(FY 2023)
- Profit 45.99%
(FY 2023)
- Ebitda 40.76%
(FY 2023)
- Net Worth -5.92%
(FY 2023)
- Total Assets -1.96%
(FY 2023)
About Astrel Genome
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 10.00 Cr and a paid-up capital of Rs 3.00 Cr, as per Ministry of Corporate Affairs (MCA) records.
Medasani Lakshmi, Asha Polavarapu, Sree Yarlagadda, and One other member serve as directors at the Company.
- CIN/LLPIN
U24230TG2005PLC045301
- Company No.
045301
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
09 Feb 2005
- Date of AGM
05 Jul 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Astrel Genome Limited offer?
Astrel Genome Limited offers a wide range of products and services, including Essential Oils, Anti Stress Essential Oils, Hair Shampoo, Herbal Shampoo, Ayurveda Products, Natural Hair & Skin Care.
Who are the key members and board of directors at Astrel Genome?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sree Yarlagadda  | Managing Director | 20-Jan-2011 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Medasani Lakshmi | Director | 02-Oct-2018 | Current |
| Asha Polavarapu | Director | 25-Feb-2013 | Current |
| Munisekhar Medasani | Director | 09-Feb-2005 | Current |
Financial Performance of Astrel Genome.
Astrel Genome Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 35.72% increase. The company also saw a substantial improvement in profitability, with a 45.99% increase in profit. The company's net worth dipped by a decrease of 5.92%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Astrel Genome?
In 2023, Astrel Genome had a promoter holding of 83.38% and a public holding of 16.62%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Aveda Life Sciences Private LimitedActive 11 years 1 monthMedasani Lakshmi and Munisekhar Medasani are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Astrel Genome?
Unlock and access historical data on people associated with Astrel Genome, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Astrel Genome, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Astrel Genome's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
